
Ajanta Pharma Q2FY27: consolidated PAT +49% YoY as margins beat guidance
Consolidated PAT for Q2 FY27 came in at ₹388 Cr, up 49% YoY (₹260 Cr) and 16% QoQ (₹334 Cr), on revenue from operations of ₹1,794 Cr, up 33% YoY and 10% QoQ. Net profit margin expanded to 21.6% from 18.4% a year ago and 19.7% last quarter. Standalone PAT was ₹380 Cr, up 52% YoY — standalone and consolidated tell the same growth story with no material divergence. Neither this quarter nor the year-ago quarter carries an exceptional item, so the YoY growth is clean rather than base-effect driven. Segment-wise, US Generics led with revenue up 41% YoY to ₹484 Cr, Africa Institution (tender-driven) revenue jumped to ₹116 Cr from ₹32 Cr (+259% YoY), and India branded generics grew a steadier 16% YoY to ₹504 Cr — ahead of IPM industry growth of 13% per IQVIA MAT September 2026 data, against Ajanta's own 17% India branded growth. Gross margin held at 78.5%, within management's guided ~78%±1% band, while adjusted EBITDA margin (excluding forex) rose to 30% from 24.2% a year ago — above the ~27%±1% full-year EBITDA guidance given on the Q3 FY26 call. The expansion is broad-based across segments rather than a single cost-line effect. On the January 2026 concall, management had guided US generics to grow in double digits for FY27 but "not at the current robust pace" — this quarter's 41% YoY US print shows that expected deceleration has not materialised yet. No Q2-specific published Street consensus was found; full-year FY27 analyst consensus pegs revenue growth at roughly 15% YoY (₹6,270 Cr), a pace H1 FY27's 29% YoY growth is already running well ahead of. The quarter also saw routine promoter-level pledge/release filings (a 30,000-share pledge on Oct 21, a 2.10% stake pledge by CTL Trusteeship on Oct 1, an NCD-linked pledge on Oct 6, and a 98,185-share release on Sep 28) — financing-related disclosures unconnected to the operating numbers. With H1 FY27 EBITDA margin at 29.1% (₹997 Cr on ₹3,420 Cr revenue) already running above the ~27%±1% full-year band, and Africa Institution's tender revenue a known swing factor, the markers into H2 are whether the US growth pace decelerates as management itself flagged and whether the institutional-tender contribution normalises from this quarter's spike.
Key Highlights
- Consolidated PAT ₹388 Cr, +49% YoY / +16% QoQ, on revenue ₹1,794 Cr, +33% YoY / +10% QoQ
- NPM expanded to 21.6% (from 18.4% YoY, 19.7% QoQ); adjusted EBITDA margin 30% vs ~27%±1% full-year guided band and 24.2% a year ago
- US Generics revenue +41% YoY to ₹484 Cr — still robust despite management's own guidance for deceleration
- Africa Institution (tender) revenue ₹116 Cr vs ₹32 Cr a year ago (+259% YoY) — lumpy, not a recurring run-rate
- India branded generics +16% YoY to ₹504 Cr; Ajanta's overall India growth of 17% beat IPM's 13% per IQVIA MAT Sep-26
- Gross margin 78.5%, within company's ~78%±1% guided band
- Standalone PAT ₹380 Cr, +52% YoY — consolidated and standalone directionally aligned
Price Impact
More from AJANTPHARM